Scholarlink

<p>Over the past decades, neoadjuvant systemic treatment (NAT) has been increasingly adopted in early-stage breast cancer (BC), highlighting the need for a more accurate assessment of treatment response. Imaging tools such as [<sup>18</sup>F]2-fluoro-2-deoxy-D-glucose ([<sup>18</sup>F]FDG) positron emission tomography combined with computed tomography (PET/CT) may enhance diagnostic accuracy in this context. By comprehensively reviewing the available literature, [<sup>18</sup>F]FDG PET/CT generally shows good sensibility but lower specificity for predicting and evaluating pathological complete response (pCR), respectively, during NAT and preoperatively, in both the breast and lymph nodes. Thereby its use may support timely escalation of systemic treatment or surgery in patients with poor metabolic response. However, definitive conclusions are limited by small, heterogeneous studies with variable patient selection, timing, and response definitions. Consequently, while international guidelines remain inconsistent, further evidence is needed to define its role in response assessment, establish the optimal use in clinical practice, and clarify its integration into (de)-escalation strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: could it become a game-changer in the scenario of the emerging (de)-escalation strategies?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Riccardo Gerosa,
  • Fabrizia Gelardi,
  • Paola Tiberio,
  • Flavia Jacobs,
  • Chiara Benvenuti,
  • Mariangela Gaudio,
  • Jacopo Canzian,
  • Benedetta Tinterri,
  • Alberto Zambelli,
  • Armando Santoro,
  • Lidija Antunovic,
  • Rita De Sanctis

摘要

Over the past decades, neoadjuvant systemic treatment (NAT) has been increasingly adopted in early-stage breast cancer (BC), highlighting the need for a more accurate assessment of treatment response. Imaging tools such as [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography combined with computed tomography (PET/CT) may enhance diagnostic accuracy in this context. By comprehensively reviewing the available literature, [18F]FDG PET/CT generally shows good sensibility but lower specificity for predicting and evaluating pathological complete response (pCR), respectively, during NAT and preoperatively, in both the breast and lymph nodes. Thereby its use may support timely escalation of systemic treatment or surgery in patients with poor metabolic response. However, definitive conclusions are limited by small, heterogeneous studies with variable patient selection, timing, and response definitions. Consequently, while international guidelines remain inconsistent, further evidence is needed to define its role in response assessment, establish the optimal use in clinical practice, and clarify its integration into (de)-escalation strategies.